Euvichol-S

**Euvichol-S** is a ready-to-use, non-adjuvanted, preservative-free oral cholera vaccine jointly developed by the International Vaccine Institute and EuBiologics for prevention of cholera caused by *Vibrio cholerae* serogroup O1. It contains formalin-inactivated whole cells of *V. cholerae* O1 Inaba El Tor strain Phil 6973 and O1 Ogawa classical strain Cairo 50. Oral administration induces protective mucosal and systemic immune responses against O1 cholera antigens, including lipopolysaccharide-associated antigens. It is a simplified, higher-productivity successor formulation to Euvichol-Plus, supplied as a 1.5 mL oral suspension and administered as two doses two weeks apart. WHO prequalified Euvichol-S on April 12, 2024. ([extranet.who.int](https://extranet.who.int/prequal/sites/default/files/vwa_vaccine/FVP-P-456_Euvichol-S_1dose_Eubiologics_WHOPAR-2025.pdf))

Brand names

Euvichol-S

Other names

OCV-S